Title: | High metabolic heterogeneity on baseline (18)FDG-PET/CT scan as a poor prognostic factor for newly diagnosed diffuse large B-cell lymphoma |
Authors: | Senjo, Hajime Browse this author |
Hirata, Kenji Browse this author →KAKEN DB |
Izumiyama, Koh Browse this author |
Minauchi, Koichiro Browse this author |
Tsukamoto, Eriko Browse this author →KAKEN DB |
Itoh, Kazuo Browse this author →KAKEN DB |
Kanaya, Minoru Browse this author |
Mori, Akio Browse this author |
Ota, Shuichi Browse this author |
Hashimoto, Daigo Browse this author →KAKEN DB |
Teshima, Takanori Browse this author →KAKEN DB |
Issue Date: | 26-May-2020 |
Publisher: | American Society of Hematology |
Journal Title: | Blood Advances |
Volume: | 4 |
Issue: | 10 |
Start Page: | 2286 |
End Page: | 2296 |
Publisher DOI: | 10.1182/bloodadvances.2020001816 |
Abstract: | Metabolic heterogeneity (MH) can be measured using F-18-fluorodeoxyglucose ((18)FDG) positron emission tomography/computed tomography (PET/CT), and it indicates an inhomogeneous tumor microenvironment. High MH has been shown to predict a worse prognosis for primary mediastinal B-cell lymphoma, whereas its prognostic value in diffuse large B-cell lymphoma (DLBCL) remains to be determined. In the current study, we investigated the prognostic values of MH evaluated in newly diagnosed DLBCL. In the training cohort, 86 patients treated with cyclophosphamide, doxorubicin, vincristine, and prednisone-like chemotherapies were divided into low-MH and high-MH groups using receiver operating characteristic analysis. MH was not correlated with metabolic tumor volume of the corresponding lesion, indicating that MH was independent of tumor burden. At 5 years, overall survivals were 89.5% vs 61.2% (P = .0122) and event-free survivals were 73.1% vs 51.1% (P = .0327) in the low- and high-MH groups, respectively. A multivariate Cox-regression analysis showed that MH was an independent predictive factor for overall survival. The adverse prognostic impacts of high MH were confirmed in an independent validation cohort with 64 patients. In conclusion, MH on baseline (18)FDG-PET/CT scan predicts treatment outcomes for patients with newly diagnosed DLBCL. |
Type: | article |
URI: | http://hdl.handle.net/2115/78746 |
Appears in Collections: | 医学院・医学研究院 (Graduate School of Medicine / Faculty of Medicine) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)
|